[Frontiers in Bioscience 15, 57-64, January 1, 2010]

Functional genomics in identification of drug targets in Dupuytren's contracture

Mirela Sedic1, Davor Jurisic2,Zdenko Stanec3, Karlo Hock1, Kresimir Pavelic1,4, Sandra Kraljevic Pavelic1,4

1Rudjer Boskovic Institute, Division of Molecular Medicine, Laboratory for systems biology, Bijenicka c. 54, 10000 Zagreb, Croatia, 2University Hospital Center Rijeka, Clinic for Surgery, Department for Plastic and Reconstructive Surgery, Kresimirova 42a, 51000 Rijeka, Croatia, 3University Hospital Dubrava, Clinic for Plastic, Reconstructive and Aesthetic Surgery, Avenija Gojka Suska 6, 10 000 Zagreb, Croatia, 4University of Rijeka, Department of, Trsat, 51000 Rijeka, Croatia, Croatia


1. Abstract
2. Introduction
3. Molecular factors involved in development of Dupuytren's contracture
4. Taking a step forward in elucidating molecular pathogenesis of Dupuytren's contracture: functional genomics
5. Perspective
6. Acknowledgements
7. References


Although functional genomics methods offer new viewpoint on molecular processes involved in particular pathological state, these methods, in particular proteomics, are still under-represented in Dupuytren's contracture research. However, several recent papers based on functional genomics technologies represent a breakthrough in studying Dupuytren's contracture as they revealed new molecular players that had been impossible to detect by traditional molecular biology methods. Using computational tools to provide biological context for such broad arrays of data accelerates the process of homing in on the potential molecular markers and drug targets. Interactomes, maps of protein-protein interactions characteristic for the disease and as such putative models of its molecular pathology, are especially useful for this purpose, facilitating the transition from global screening methods to specific experiments aimed at therapy development. The combination of these approaches in Dupuytren's contracture research might therefore facilitate the discovery of novel therapeutic targets and diagnostic markers indicative of disease progression.